Skip to main content

TIL

Stock

TIL

Stock
Health Care
Biotechnology

Performance overview

TIL Price
Price Chart

Forward-looking statistics

Beta
1.17
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Company info

SectorHealth Care
IndustryBiotechnology
Employees192
Market cap$69.6M

Fundamentals

Enterprise value$119.7M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity59.81

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$11.97
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$11M
Avg trading volume (10 day)$8M
Put-call ratio—

Macro factor sensitivity

Growth-0.3
Credit+4.4
Liquidity-2.9
Inflation-4.4
Commodities+0.5
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-2.28
Price to sales—
P/E Ratio-2.28
Enterprise Value to Revenue—
Price to book1.24

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

4 Discretionary Stocks to Buy as Consumer Sentiment Rebounds

FUBO, CCL, LOPE, and TILE stand out as top picks as consumer sentiment sees its biggest monthly jump in over 30 years.

Zacks Investment Research (July 1, 2025)
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research (June 20, 2025)
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns

Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.

Zacks Investment Research (June 17, 2025)
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.

Benzinga (January 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free